Market Overview

Eli Lilly Reassumes Sole Worldwide Development, Commercialization Role for Novel Basal Insulin Analog

Related LLY
Healthcare Spending to Trend Up in 2015: 3 Healthcare Fund Picks - Best of Funds
Eli Lilly Beats on Q2 Earnings & Revs, Maintains View
Eli Lilly Bets Big on Diabetes, Cancer Drugs (Fox Business)

Eli Lilly and Company (NYSE: LLY) and Boehringer Ingelheim International GmbH announced today they will adjust the scope of their diabetes alliance with respect to LY2605541*, Lilly's novel basal insulin analog, with Lilly reassuming sole worldwide development and commercialization rights to LY2605541. 

Lilly and Boehringer Ingelheim formed their diabetes alliance in January 2011, centering on four pipeline compounds representing several of the largest and most promising product classes. It is one of the largest alliances among two pharmaceuticals companies ever in a single therapeutic area and aims to provide a broad portfolio of treatment options for patients with diabetes and their healthcare professionals.

While Lilly and Boehringer Ingelheim will continue to jointly develop and commercialize the other assets in the alliance, Boehringer Ingelheim elected to terminate the collaboration with Lilly with respect to LY2605541 given independent strategic portfolio considerations.

Posted-In: News

 

Most Popular

Related Articles (LLY)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters